Proteomic profiling: The potential of Seldi-Tof for the identification of new cancer biomarkers;Protéomique et signature tumorale: Identification de nouveaux marqueurs par l'approche Seldi-Tof

Bulletin du Cancer

Volumn 92, Issue 9, 2005, Pages 763-768

  Solassol, Jérôme ^a   Marin, Philippe ^b   Maudelonde, Thierry ^a   Mangé, Alain ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

Biomarker; Proteomic; Seldi Tof

Indexed keywords

TUMOR MARKER;

CANCER; CANCER DIAGNOSIS; DRUG EFFICACY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HUMAN; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL TIME; TECHNOLOGY;

FORECASTING; HUMANS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 26844435043     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. MacNeil JS. Better biomarkers for the diagnostics labyrinth. Genome Technol 2004: 24-33.
2. Bellet D, Lazar V, de Paillerets BB, Bennaceur-Griscelli A, Benard J, Bidart JM. Evolution of cancer markers: from radio-immunology to DNA chips and from surveillance to forecasting. Bull Cancer 2000; 87: 35-9.
3. Lescuyer P, Chevallet M, Rabilloud T. Concepts and therapeutic perspectives of proteomics. Med Sci (Paris) 2004; 20: 587-92.
4. Petricoin EF, Liotta LA. Seldi-Tof-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24-30.
5. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and Maldi-Tof mass spectrometry. Anal Chem 2004; 76: 1560-70.
6. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004; 65: 2426-34.
7. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 149-56.
8. Govorukhina NI, Keizer-Gunnink A, van der Zee AG, de Jong S, de Bruijn HW, Bischoff R. Sample preparation of human serum for the analysis of tumor markers: comparison of different approaches for albumin and gamma-globulin depletion. J Chromatogr A 2003; 1009: 171-8.
9. Chaurand P, Schwartz SA, Caprioli RM. Assessing protein patterns in disease using imaging mass spectrometry. J Proteome Res 2004; 3: 245-52.
10. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
11. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360: 169; [author reply: 170-1].
12. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004; 11: 163-78.
13. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-8.
14. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
15. Zhang Z, Bast Jr. RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
16. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-11.
17. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62: 1868-75.
18. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158: 1491-502.
19. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005; 41: 40-7.
20. Hlavaty JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003; 61: 1261-5.
21. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96: 353-6.
22. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360: 170.
23. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
24. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425: 905.
25. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2003; 19: 1-10.
26. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-64.
27. Matrisian LM, Sledge GW, Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res 2003; 63: 6105-9.
28. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22: 184-204.
29. Remy L, Bellaton C, Pourreyron C, Anderson W, Pereira A, Dumortier J, et al. Integrins and metalloproteinases: an efficient collaboration in the invasive process. Bull Cancer 1999; 86: 154-8.
30. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-78.
31. Baggerly KA, Morris JS, Coombes KR. Reproducibility of Seldi-Tof protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004; 20: 777-85.
32. Petricoin 3rd E, Liotta LA. Counterpoint: The vision for a new diagnostic paradigm. Clin Chem 2003; 49: 1276-8.
33. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49: 1272-5.
34. Chauvet B, Villers A, Davin JL, Nahon S. Update on screening, diagnosis and treatment of cancer of the prostate. Bull Cancer 2002; 89: 37-45.
35. Solassol J, Marin P, Demettre E, Rouanet P, Bockaert J, Maudelonde T, et al. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 2005; 338: 26-31.
36. Wang YY, Cheng P, Chan DW. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003; 3: 243-8.
37. Merrell K, Southwick K, Graves SW, Esplin MS, Lewis NE, Thulin CD. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 2004; 15: 238-48.
38. Rai AJ, Zhang Z, Rosenzweig J, Shih Ie M, Pham T, Fung ET, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518-26.
39. Petricoin 3rd EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8.
40. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-43.
41. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170: 442-6.
42. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003; 92: 223-5.
43. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002; 8: 2541-52.
44. Wellmann A, Wollscheid V, Lu H, Ma ZL, Albers P, Schutze K, et al. Analysis of microdissected prostate tissue with ProteinChip arrays: a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 2002; 9: 341-7.
45. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4: 203-9.
46. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
47. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, et al. Surfaced-enhanced laser desorption/ionization time-of-flight (Seldi-Tof) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004; 11: 907-14.
48. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004; 100: 1814-22.
49. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, et al. Proteomic patterns of nipple aspirate fluids obtained by Seldi-Tof: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17: 301-7.
50. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using Seldi-Tof-MS. Int J Cancer 2004; 17: 17.
51. Kuerer HM, Coombes KR, Chen JN, Xiao L, Clarke C, Fritsche H, et al. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 2004; 136: 1061-9.
52. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-8.
53. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by Seldi mass spectrometry. Lung Cancer 2003; 40: 267-79.
54. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003; 19: 33-9.
55. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003; 63: 6971-83.
56. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003; 3: 2310-6.
57. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004; 10: 4806-12.
58. Wadsworth JT, Somers KD, Stack Jr BC, Cazares L, Malik G, Adam BL, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004; 130: 98-104.
59. Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, et al. Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip (R) technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol Cell Proteomics 2003; 2: 443-52.
60. Melle C, Kaufmann R, Hommann M, Bleul A, Driesch D, Ernst G, et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 2004; 24: 885-91.
61. Wilson LL, Tran L, Morton DL, Hoon DS. Detection of differentially expressed proteins in early-stage melanoma patients using Seldi-Tof mass spectrometry. Ann N Y Acad Sci 2004; 1022: 317-22.
62. Krieg RC, Fogt F, Braunschweig T, Herrmann PC, Wollscheidt V, Wellmann A. ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res 2004; 24: 1791-6.
63. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the Seldi ProteinChip platform. Biochem Biophys Res Commun 2003; 309: 18-25.
64. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004; 10: 8380-5.
65. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004; 211: 227-34.